Litcius/Paper detail

SARS-CoV-2 receptor is co-expressed with elements of the kinin–kallikrein, renin–angiotensin and coagulation systems in alveolar cells

Davi Sidarta-Oliveira, Carlos Poblete Jara, Adriano José Ferruzzi, Munir S. Skaf, William H. Velander, Eliana P. Araújo, Lı́cio A. Velloso

2020Scientific Reports51 citationsDOIOpen Access PDF

Abstract

SARS-CoV-2, the pathogenic agent of COVID-19, employs angiotensin converting enzyme-2 (ACE2) as its cell entry receptor. Clinical data reveal that in severe COVID-19, SARS-CoV-2 infects the lung, leading to a frequently lethal triad of respiratory insufficiency, acute cardiovascular failure, and coagulopathy. Physiologically, ACE2 plays a role in the regulation of three systems that could potentially be involved in the pathogenesis of severe COVID-19: the kinin-kallikrein system, resulting in acute lung inflammatory edema; the renin-angiotensin system, promoting cardiovascular instability; and the coagulation system, leading to thromboembolism. Here we assembled a healthy human lung cell atlas meta-analysis with ~ 130,000 public single-cell transcriptomes and show that key elements of the bradykinin, angiotensin and coagulation systems are co-expressed with ACE2 in alveolar cells and associated with their differentiation dynamics, which could explain how changes in ACE2 promoted by SARS-CoV-2 cell entry result in the development of the three most severe clinical components of COVID-19.

Topics & Concepts

BradykininRenin–angiotensin systemAngiotensin-converting enzyme 2ImmunologyReceptorCoagulationLungAngiotensin IIPathogenesisMedicineBiologyInternal medicineCoronavirus disease 2019 (COVID-19)Blood pressureInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19
SARS-CoV-2 receptor is co-expressed with elements of the kinin–kallikrein, renin–angiotensin and coagulation systems in alveolar cells | Litcius